Matthias Forstmann

Researcher; formerly affiliated with Yale University and linked to psychedelic research in psychology/social perception

Data updated

Papers

6 publications

Trials

0 clinical trials

Research Footprint

Matthias Forstmann appears in 6 tracked papers (2017–2023), most studied alongside LSD, Psilocybin and DMT, across Substance Use Disorders (SUD), Personality & Trait Factors and Interpersonal Functioning & Social Connectedness.

Most-cited paper: Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings (184 citations).

Frequent co-authors: Robin Carhart-Harris, David Luke and Sam Gandy.

Background & Research

Matthias Forstmann is a psychologist/researcher who has coauthored multiple influential studies on psychedelics, including work on nature relatedness, pro-environmental behavior, and perceived scientific integrity of psychedelic researchers. His publications also examine transformative experience, social connectedness, and the mood-enhancing effects of psychedelic use in naturalistic settings.

Key Impact

He is a notable contributor to psychedelic science on nature relatedness, pro-environmental behavior, and social/mood effects of psychedelic use, with work cited across both basic and applied psychedelic research.

6

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

6 collaborators· click a node to visit their profile

Full network →

Compounds

LSDPsilocybinDMTMescalineMDMAIbogaineKetamineSalvia Divinorum

Topics

Substance Use Disorders (SUD)Personality & Trait FactorsInterpersonal Functioning & Social ConnectednessMajor Depressive Disorder (MDD)Depressive DisordersAnxiety DisordersPalliative & End-of-Life DistressHealthy VolunteersCreativityMedicinal Chemistry & Drug DevelopmentSet & Setting

Top Collaborators

Affiliations

Institutions, companies, and organisations Matthias Forstmann is associated with.

University of Zurich

academic

Within the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.

View stakeholder →

Yale University

academic

In 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.

View stakeholder →